The Change in the Dihydrotestosterone Level in the Prostate Before and After Androgen Deprivation Therapy in Connection With Prostate Cancer Aggressiveness Using the Gleason Score

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1282-1289

  Nishiyama, Tsutomu ^a   Ikarashi, Toshihiko ^b   Hashimoto, Yutaka ^c   Wako, Koichi ^a   Takahashi, Kota ^a  

^a Division of Urology   (Japan)

^b Department of Pathology Niigataken Kouseiren Byori Center ^*  (Japan)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

adrenal androgens; androgens; dihydrotestosterone; prostate; prostatic neoplasms

Indexed keywords

ANDROSTANOLONE; FLUTAMIDE; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DERIVATIZATION; DRUG EFFECT; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; GLEASON SCORE; HORMONE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MALE; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; FLUTAMIDE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34548383053     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.138     Document Type: Article

References (19)

1. Gleason D.F. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M. (Ed). Urologic Pathology (1977), Lea and Febiger, Philadelphia 171-198
2. Benaim E.A., Pace C.M., and Roehrborn C.G. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 42 (2002) 12
3. Albertsen P.C., Hanley J.A., and Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
4. Nishiyama T., Ikarashi T., Hashimoto Y., and Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176 (2006) 1387
5. Nishiyama T., Hashimoto Y., and Takahashi K. The influence of androgen eprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 (2004) 7121
6. Geller J., and Albert J.D. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 15 (1987) 151
7. Labrie F., Belanger A., Dupont A., Luu-The V., Simard J., and Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16 (1993) 475
8. Bartsch W., Klein H., Schiemann U., Bauer H.W., and Voigt K.D. Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci 595 (1990) 53
9. Mizokami A., Koh E., Fujita H., Maeda Y., Egawa M., Koshida K., et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64 (2004) 765
10. Mohler J.L., Gregory C.W., Ford III O.H., Kim D., Weaver C.M., Petrusz P., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440
11. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653
12. Koh E., Noda T., Kanaya J., and Namiki M. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 (2002) 154
13. Nakamura Y., Suzuki T., Nakabayashi M., Endoh M., Sakamoto K., Mikami Y., et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12 (2005) 101
14. Fung K.M., Samara E.N., Wong C., Metwalli A., Krlin R., Bane B., et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13 (2006) 169
15. Kitagawa Y., Koshida K., Mizokami A., Komatsu K., Nakashima S., Misaki T., et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 10 (2003) 377
16. Hussain M., Tangen C.M., Higano C., Schelhammer P.F., Faulkner J., Crawford E.D., et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984
17. Ryan C.J., Smith A., Lal P., Satagopan J., Reuter V., Scardino P., et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 68 (2006) 834
18. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815
19. Ji Q., Chang L., Stanczyk F.Z., Ookhtens M., Sherrod A., and Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67 (2007) 1361